21:12 , Feb 22, 2018 |  BC Innovations  |  Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
00:26 , Jan 25, 2018 |  BC Extra  |  Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday. Spark will receive $105 million up front and...
20:43 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

FDA approves Prexxartan to treat hypertension

Medicure Inc. (TSX-V:MPH; PINK:MCUJF) said FDA granted final approval to an NDA from Carmel Biosciences Inc. (Atlanta, Ga.) for Prexxartan valsartan oral solution to treat hypertension in patients ages six and older, heart failure and...
01:10 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Renal

INDICATION: Renal damage Cell culture and rat studies identified a benzimidazole-based TRPC5 inhibitor that could help treat focal segmental glomerulosclerosis (FSGS). Chemical synthesis and testing in HEK cell-based ion channel activity assays of a library...
21:20 , Nov 22, 2017 |  BC Extra  |  Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
21:21 , Jun 22, 2017 |  BC Extra  |  Clinical News

Novartis' canakinumab cuts CV risk in MI patients

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab ( ACZ885 ) plus standard of care reduced cardiovascular risk in patients with a prior heart attack and inflammatory atherosclerosis in the Phase III CANTOS trial. The mAb against...
22:55 , Apr 25, 2017 |  BC Extra  |  Company News

Novartis confident in 2017 Entresto goal

Novartis AG (NYSE:NVS; SIX:NOVN) believes sales of heart failure drug Entresto sacubitril/valsartan can reach the company's $500 million goal this year, although the company's 1Q17 earnings report released Tuesday said sales were $84 million for...
22:31 , Mar 10, 2017 |  BioCentury  |  Product Development

Shock options

While investors were quick to bid up shares of La Jolla Pharmaceutical Co. after LJPC-501 met the primary blood pressure endpoint in a Phase III trial in distributive shock, at least some physicians are questioning...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
00:53 , Jan 26, 2017 |  BC Extra  |  Company News

Novartis mulls Alcon options, reports earnings

In its 4Q16 earnings report, Novartis AG (NYSE:NVS; SIX:NOVN) said it is mulling an IPO or spin-out of its Alcon Inc. surgical and vision care division. Sales in the division were $5.8 billion, off 2%...